View ValuationSunny Pharmtech 将来の成長Future 基準チェック /06現在、 Sunny Pharmtechの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長15.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 23Sunny Pharmtech Inc., Annual General Meeting, Jun 26, 2026Sunny Pharmtech Inc., Annual General Meeting, Jun 26, 2026. Location: 4 floor building. o no,255, lung yuan 1st rd., longtan district, taoyuan city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$153m free cash flow). Earnings have declined by 2.5% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (NT$2.75b market cap, or US$87.3m).New Risk • Jan 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$153m free cash flow). Earnings have declined by 2.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (NT$2.53b market cap, or US$80.1m).Reported Earnings • Apr 27Full year 2024 earnings released: NT$1.05 loss per share (vs NT$0.44 loss in FY 2023)Full year 2024 results: NT$1.05 loss per share (further deteriorated from NT$0.44 loss in FY 2023). Revenue: NT$418.0m (down 2.5% from FY 2023). Net loss: NT$156.0m (loss widened 146% from FY 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.New Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (NT$2.13b market cap, or US$64.6m).お知らせ • Mar 28Sunny Pharmtech Inc., Annual General Meeting, Jun 16, 2025Sunny Pharmtech Inc., Annual General Meeting, Jun 16, 2025. Location: 4 floor building. o no,255, lung yuan 1st rd., longtan district, taoyuan city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$3.05b market cap, or US$92.6m).New Risk • Nov 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.25b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risk Market cap is less than US$100m (NT$3.25b market cap, or US$99.7m).New Risk • Aug 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$112m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).New Risk • Jul 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).Reported Earnings • Apr 18Full year 2023 earnings released: NT$0.44 loss per share (vs NT$1.23 loss in FY 2022)Full year 2023 results: NT$0.44 loss per share (improved from NT$1.23 loss in FY 2022). Revenue: NT$428.8m (up 19% from FY 2022). Net loss: NT$63.3m (loss narrowed 63% from FY 2022).お知らせ • Apr 04Sunny Pharmtech Inc., Annual General Meeting, Jun 27, 2024Sunny Pharmtech Inc., Annual General Meeting, Jun 27, 2024.New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).New Risk • Oct 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risk Shareholders have been diluted in the past year (7.2% increase in shares outstanding).New Risk • Sep 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).Reported Earnings • Aug 15First half 2023 earnings released: NT$0.38 loss per share (vs NT$0.77 loss in 1H 2022)First half 2023 results: NT$0.38 loss per share (improved from NT$0.77 loss in 1H 2022). Revenue: NT$177.4m (up 14% from 1H 2022). Net loss: NT$52.1m (loss narrowed 51% from 1H 2022).Reported Earnings • Apr 12Full year 2022 earnings released: NT$1.23 loss per share (vs NT$1.31 loss in FY 2021)Full year 2022 results: NT$1.23 loss per share (improved from NT$1.31 loss in FY 2021). Revenue: NT$359.6m (up 49% from FY 2021). Net loss: NT$170.2m (loss narrowed 2.6% from FY 2021).Reported Earnings • Aug 15First half 2022 earnings released: NT$0.77 loss per share (vs NT$0.76 loss in 1H 2021)First half 2022 results: NT$0.77 loss per share (down from NT$0.76 loss in 1H 2021). Revenue: NT$155.4m (up 27% from 1H 2021). Net loss: NT$106.4m (loss widened 7.5% from 1H 2021).お知らせ • Apr 04Sunny Pharmtech Inc., Annual General Meeting, Jun 30, 2022Sunny Pharmtech Inc., Annual General Meeting, Jun 30, 2022. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Sunny Pharmtech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:6676 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025253-302-193-159N/A9/30/2025272-286-173-136N/A6/30/2025290-270-153-113N/A3/31/2025354-213-120-75N/A12/31/2024418-156-87-37N/A9/30/2024452-103-99-24N/A6/30/2024485-50-112-11N/A3/31/2024457-57-11013N/A12/31/2023429-63-10738N/A9/30/2023405-90-8051N/A6/30/2023382-116-5264N/A3/31/2023371-143-11045N/A12/31/2022360-170-16827N/A9/30/2022317-176-2074N/A6/30/2022274-182-246-18N/A3/31/2022257-179-221-26N/A12/31/2021241-175-195-34N/A9/30/2021277-162-235-88N/A6/30/2021312-150-274-142N/A3/31/2021366-126-185-84N/A12/31/2020420-102-95-26N/A9/30/2020426-112-1449N/A6/30/2020432-12167123N/A3/31/2020333-174-653N/A12/31/2019234-226-198-118N/A9/30/2019194-260N/A-209N/A6/30/2019153-295N/A-300N/A3/31/2019148-297N/A-303N/A12/31/2018143-300N/A-306N/A9/30/201886-302N/A-303N/A6/30/201830-304N/A-301N/A3/31/201826-287N/A-278N/A12/31/201722-269N/A-255N/A9/30/201718-256N/A-236N/A6/30/201715-243N/A-217N/A3/31/201720-235N/A-213N/A12/31/201624-227N/A-210N/A12/31/201515-146N/A-230N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6676の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6676の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6676の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6676の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6676の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6676の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 15:41終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sunny Pharmtech Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 23Sunny Pharmtech Inc., Annual General Meeting, Jun 26, 2026Sunny Pharmtech Inc., Annual General Meeting, Jun 26, 2026. Location: 4 floor building. o no,255, lung yuan 1st rd., longtan district, taoyuan city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$153m free cash flow). Earnings have declined by 2.5% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (NT$2.75b market cap, or US$87.3m).
New Risk • Jan 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$153m free cash flow). Earnings have declined by 2.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (NT$2.53b market cap, or US$80.1m).
Reported Earnings • Apr 27Full year 2024 earnings released: NT$1.05 loss per share (vs NT$0.44 loss in FY 2023)Full year 2024 results: NT$1.05 loss per share (further deteriorated from NT$0.44 loss in FY 2023). Revenue: NT$418.0m (down 2.5% from FY 2023). Net loss: NT$156.0m (loss widened 146% from FY 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
New Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (NT$2.13b market cap, or US$64.6m).
お知らせ • Mar 28Sunny Pharmtech Inc., Annual General Meeting, Jun 16, 2025Sunny Pharmtech Inc., Annual General Meeting, Jun 16, 2025. Location: 4 floor building. o no,255, lung yuan 1st rd., longtan district, taoyuan city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$3.05b market cap, or US$92.6m).
New Risk • Nov 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.25b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risk Market cap is less than US$100m (NT$3.25b market cap, or US$99.7m).
New Risk • Aug 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$112m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).
New Risk • Jul 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).
Reported Earnings • Apr 18Full year 2023 earnings released: NT$0.44 loss per share (vs NT$1.23 loss in FY 2022)Full year 2023 results: NT$0.44 loss per share (improved from NT$1.23 loss in FY 2022). Revenue: NT$428.8m (up 19% from FY 2022). Net loss: NT$63.3m (loss narrowed 63% from FY 2022).
お知らせ • Apr 04Sunny Pharmtech Inc., Annual General Meeting, Jun 27, 2024Sunny Pharmtech Inc., Annual General Meeting, Jun 27, 2024.
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).
New Risk • Oct 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risk Shareholders have been diluted in the past year (7.2% increase in shares outstanding).
New Risk • Sep 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding).
Reported Earnings • Aug 15First half 2023 earnings released: NT$0.38 loss per share (vs NT$0.77 loss in 1H 2022)First half 2023 results: NT$0.38 loss per share (improved from NT$0.77 loss in 1H 2022). Revenue: NT$177.4m (up 14% from 1H 2022). Net loss: NT$52.1m (loss narrowed 51% from 1H 2022).
Reported Earnings • Apr 12Full year 2022 earnings released: NT$1.23 loss per share (vs NT$1.31 loss in FY 2021)Full year 2022 results: NT$1.23 loss per share (improved from NT$1.31 loss in FY 2021). Revenue: NT$359.6m (up 49% from FY 2021). Net loss: NT$170.2m (loss narrowed 2.6% from FY 2021).
Reported Earnings • Aug 15First half 2022 earnings released: NT$0.77 loss per share (vs NT$0.76 loss in 1H 2021)First half 2022 results: NT$0.77 loss per share (down from NT$0.76 loss in 1H 2021). Revenue: NT$155.4m (up 27% from 1H 2021). Net loss: NT$106.4m (loss widened 7.5% from 1H 2021).
お知らせ • Apr 04Sunny Pharmtech Inc., Annual General Meeting, Jun 30, 2022Sunny Pharmtech Inc., Annual General Meeting, Jun 30, 2022.